A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate®P/Humate®-P: History and clinical performance

European Journal of Haematology

Volumn 80, Issue SUPPL. 70, 2008, Pages 3-35

  Berntorp, Erik ^a   Archey, William ^b   Auerswald, Günter ^c   Federici, Augusto B ^d   Franchini, Massimo ^e   Knaub, Sigurd ^f   Kreuz, Wolfhart ^g   Lethagen, Stefan ^a   Mannucci, Pier M ^d   Pollmann, Hartmut ^h   Scharrer, Inge ⁱ   Hoots, Keith ^j  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b nspm Ltd   (Switzerland)

^c KLINIKUM BREMEN MITTE   (Germany)

^d UNIVERSITY OF MILAN   (Italy)

^e City Hospital of Verona   (Italy)

^f CSL BEHRING GMBH   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h Institut für Thrombophilie und Hämostaseologie   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Factor VIII; Haemate P; Haemophilia; Humate P; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; VON WILLEBRAND FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASTHENIA; BLEEDING; CONTINUOUS INFUSION; COUGHING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FEVER; HEADACHE; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; LOADING DRUG DOSE; LUNG EMBOLISM; NAUSEA; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; PUBLICATION; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHLEBITIS; URTICARIA; VIRUS INACTIVATION; VON WILLEBRAND DISEASE;

EID: 41749108922     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01049.x     Document Type: Review

References (218)

1. Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood 1992 79: 2507 19.
2. Goodall AH Advances in immunochemical aspects of VWD. In: Seghatchian MJ, Savidge GF eds. Factor VIII - von Willebrand Factor, vol. 1, 1st edn. Boca Raton, FL: CRC Press Inc, 1989: 147 71.
3. Roberts HR, Monroe DM, Hoffman M Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Beutler E, ed. Williams Hematology, 6th edn. New York: McGraw-Hill, 2001: 1409 34.
4. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981 57: 1140 3.
5. Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease. Blood 1987 70: 895 904.
6. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992 67: 594 9.
7. Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci U S A 2006 103: 18470 4.
8. Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 1984 63: 128 39.
9. Weiss HJ, Turitto VT, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood 1986 67: 322 30.
10. Meyer D, Girma JP. von Willebrand factor: structure and function. Thromb Haemost 1993 70: 99 104.
11. Weiss HJ. von Willebrand factor and platelet function. Ann N Y Acad Sci 1991 614: 125 37.
12. Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, Van Mourik JA, Sixma JJ. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem 1987 166: 37 43.
13. Hamer RJ, Koedam JA, Beeser-Visser NH, Sixma JJ. The effect of thrombin on the complex between factor VIII and von Willebrand factor. Eur J Biochem 1987 167: 253 9.
14. Handin RI, Wagner DD. Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb 1989 9: 233 59.
15. Hoyer LW. The factor VIII complex: structure and function. Blood 1981 58: 1 13.
16. Hoyer LW. Hemophilia A. N Engl J Med 1994 330: 38 47.
17. Kaufmann RJ. Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology. Ann Hematol 1991 63: 155 65.
18. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988 82: 1236 43.
19. Fay PJ. Factor VIII structure and function. Thromb Haemost 1993 70: 63 7.
20. Jacquemin M, Neyrinck A, Hermanns MI, Lavend'homme R, Rega F, Saint-Remy JM, et al. FVIII production by human lung microvascular endothelial cells. Blood 2006 108: 515 7.
21. Eaton D, Rodriguez A, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986 25: 502 12.
22. Rotblat F, O'Brien DP, O'Brien FJ, Goodall AH, Tuddenham EG. Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. Biochemistry 1985 24: 4294 300.
23. Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem 1990 189: 229 34.
24. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003 88: 94 108.
25. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987 69: 454 9.
26. Hedner U, Ginsburg D, Lusher JM, High KA. Congenital hemorrhagic disorders: new insights into the pathophysiology and treatment of hemophilia. Hematology 2000 1: 241 65.
27. Siegmund B, Richter H, Pollmann H. Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes. Haemophilia 2007 13: 21 5.
28. Holmberg L, Nilsson IM. von Willebrand's disease. Eur J Haematol 1992 48: 127 41.
29. Kasper CK. Von Willebrand Disease: An Introductory Discussion for Young Physicians. Available at: http://www.med.unc.edu/isth/publications/ vwd_monograph/VWD_monograph_2005.pdf ; created 2005; last accessed on 17 October 2007.
30. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998 92:2707 11.
31. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000 84:345 9.
32. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006 43:S48 S58.
33. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007 82:368 75.
34. Michiels JJ, Berneman Z, Gadisseur A, van der PM, Schroyens W, Budde U, et al. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 2006 32:577 88.
35. Vincentelli A, Susen S, Le TT, Six I, Fabre O, Juthier F, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003 349:343 9.
36. Dalton RG, Savidge GF Progress in VWf methodology and its relevance in VWD. In:Seghatchian MJ, Savidge GF eds. Factor VIII - von Willebrand Factor, vol. 1, 1st edn. Boca Raton, FL:CRC Press Inc, 1989:129 45.
37. Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997 78:930 3.
38. Favoloro EJ. Collagen binding assay for von Willebrand Factor (VWF:CBA). Detection of von Willebrands disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000 83:127 35.
39. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994 71:520 5.
40. Sadler JE. Appendix II: A revised classification of Von Willebrand disease. Haemophilia 1997 3 (Suppl. 2 11 8.
41. Blood Center of Wisconsin Hemostasis Reference Laboratory. Von Willebrand Disease: Laboratory Evaluation. Available at: http://www.bloodcenter.com/bins/ site/content/public/laboratory%20testing/test%20catalog/test%20descriptions/ von%20Willebrand%20Disease%20Laboratory%20Evaluation.pdf ; created 2003; last accessed on 21 November 2007.
42. Schneppenheim R. The evolving classification of von Willebrand disease. Blood Coagul Fibrinolysis 2005 16 (Suppl. 1 S3 S10.
43. Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002 28:173 90.
44. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in Type IIA von Willebrand factor. Proc Natl Acad Sci U S A 1990 87:6306 10.
45. Siediecki CA, Lestini BJ, Kottke-Marchant K, Eppell SJ, Wilson DL, Marchant RE. Shear-dependant changes in the three-dimensional structure of human von Willebrand factor. Blood 1996 88:2939 50.
46. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994 83:2171 9.
47. Anderson RP, McGrath K, Street A. Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement. Lancet 1996 347:689 90.
48. Cappel MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasias after aortic valve replacement. Ann Intern Med 1986 105:54 7.
49. Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000 102:1290 5.
50. Enayat MS, Guilliatt AM, Lester W, O'Connor NTJ, Williams MD, Hill FGH. Pseudo von Willebrand disease: 2B or not 2B? Cryoprecipitate induced platelet aggregation solves Hamlet's dilemma. J Thromb Haemost 2005 3 (Suppl. 1 abstract P1470).
51. Monrigal C, Fressinaud E, Shoay I, Monrigal JP, Granry JC. [A rare hemostatic disorder: pseudo von Willebrand's disease]. Ann Fr Anesth Reanim 1989 8:662 6.
52. Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost 2006 32:555 65.
53. Brettler DB, Levine PH Clinical manifestations and therapy of inherited coagulation factor deficiencies. In:Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis - Basic Principles and Clinical Practice, 3rd edn. Philadelphia, PA:J.B. Lippincott Company, 1994:169 83.
54. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the Scientific Subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001 85:560.
55. Carlebjork G, Oswaldsson U, Rosen S. A simple and accurate microplate assay for the determination of factor VIII activity. Thromb Res 1987 47:5 14.
56. Beard J, Savidge GF. Clinical and laboratory assessment of patients with haemophilia. In:Seghatchian MJ, Savidge GF, eds. Factor VIII - von Willebrand Factor, vol. II. Boca Raton, FL:CRC Press Inc, 1989:33 48.
57. Montgomery RR, Coller BS. Von Willebrand disease. In:Colman RW, ed. Hemostasis and Thrombosis - Basic Principles and Clinical Practice. Philadelphia, PA:JB Lippincott Co, 1994:134 68.
58. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005 16:S17 S21.
59. Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001 66:280 4.
60. Cattaneo M, Fischer B, Mannucci PM. Diagnosis and treatment of von Willebrand's disease. J Pediatr Hematol Oncol 1994 1:499 508.
61. Scharrer I. Women with von Willebrand disease. Haemostaseologie 2004 24:44 9.
62. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, et al. Biologic response to desmopressin in patients with severe Type 1 and Type 2 von Willebrand disease: results of a multicenter European study. Blood 2004 103:2032 8.
63. Lusher JM. Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. Haemostasis 1994 24:276 84.
64. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977 1:869 72.
65. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988 72:1449 55.
66. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992 82:87 93.
67. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000 84:160 74.
68. Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 2001 7 (Suppl. 1 10 5.
69. Federici AB, Mannucci PM. Diagnosis and management of von Willebrands disease. Haemophilia 1999 5 (Suppl. 2 28 37.
70. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease Type 3. Semin Thromb Hemost 2006 32:621 5.
71. Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006 118 (Suppl. 1 S9 S11.
72. Brettler DB, Kraus EM, Levine PH. Clinical aspects of and therapy for haemophilia A. In:Hoffman R, ed. Hematology: Basic Principles and Practice. New York:Churchill Livingstone Inc, 1995:1648 63.
73. Leissinger C, Becton D, Cornell C, Cox GJ. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate Type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001 7:258 66.
74. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de KP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002 99:2337 41.
75. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007 357:535 44.
76. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PL, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003 9:1 4.
77. Martinowitz U, Schulman S, Horoszowski H, Heim M. Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. Clin Orthop Relat Res 1996 328:65 75.
78. Rakocz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. Dental extractions in patients with bleeding disorders. The use of fibrin glue. Oral Surg Oral Med Oral Pathol 1993 75:280 2.
79. Yanagiya K, Tanaka T, Sakamoto Y, Komori T, Matsumoto K, Ohkoshi M, et al. Clinical application of Beriplast P in oral surgery. Hayaku Ryohoh 1992 1992 11:174 9.
80. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992 339:594 8.
81. Kreuz W, Auerswald G. Immune tolerance therapy in pediatric hemophiliacs with Factor VIII Inhibitors. Biomedical Progress 1996 9:57 62.
82. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Gungor T, Kornhuber B. Epidemiology of inhibitors in haemophilia A. Vox Sang 1996 70:2 8.
83. Kreuz W Immune tolerance and choice of concentrates. In:Rodriguez-Merchan EC, Lee CA eds. Inhibitors in Patients with Haemophilia, 1st edn. Oxford:Blackwell Science, 2002:55 8.
84. Meili EO. Treatment of hemophilia. Schweiz Med Wochenschr 1991 43 (Suppl. 43 82 9.
85. Schimpf K. [The role of self-infusion treatment for the patient with haemophilia]. Blut 1978 36:63 71 (author's transl.).
86. Kreuz W, Ehrenforth S, Funk M, Auerswald G, Mentzer D, Joseph-Steiner J, et al. Immune tolerance therapy in pediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995 1:24 32.
87. Scandella D. Epitope specificity of factor VIII inhibitor antibodies. Haemostaseologie 1998 18:121 8.
88. Gensana M, Altisent C, Aznar JA, Casana P, Hernandez F, Jorquera JI, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001 7:369 74.
89. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003 88 (Suppl. 9 21 5.
90. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984 150:181 95.
91. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999 77:49 54.
92. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995 86:983 8.
93. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988 259:65 8.
94. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 1999 5:32 9.
95. Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 2003 88 (Suppl. 9 13 6.
96. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005 16 (Suppl. 1 S27 S31.
97. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006 12 (Suppl. 6 102 6.
98. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996 76:749 54.
99. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003 9:418 35.
100. Astermark J, Voorberg J, Lenk H, Dimichele D, Shapiro A, Tjonnfjord G, et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003 9:567 72.
101. Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007 13:51 6.
102. Dasgupta S, Repesse Y, Bayry J, Navarrete AM, Wootla B, Delignat S, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007 109:610 2.
103. Penner JA. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response. Haemophilia 2001 7:103 8.
104. Di Michele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-97; current practice implications. Vox Sang 1999 77 (Suppl. 1 31 2.
105. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995 125:348 55.
106. Di Michele DM, Miller CH Successful induction of immune tolerance (IT) in a patient with severe von Willebrand's disease (VWD) and an inhibitor. Haemophilia 1996 2 (Suppl. 1 abstract 422).
107. Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987 39:467 70.
108. Scaraggi FA Combined treatment with intermediate purity factor VIII concentrate and recombinant factor VIII in Type 3 von Willebrand disease and anti-von Willebrand antibodies. Haemophilia 2006 12 (Suppl. 2 abstract PO 423).
109. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004 351:683 94.
110. Federici AB. Management of inherited von Willebrand disease in 2006. Semin Thromb Hemost 2006 32:616 20.
111. Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multi-therapeutic approach to manage delivery in an alloimmunized patient with Type 3 von Willebrand disease. J Thromb Haemost 2003 1:190 2.
112. Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988 40:205 14.
113. Lawrie AS, Harrison P, Armstrong AL, Wilbourn BR, Dalton RG, Savidge GF. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates. Br J Haematol 1989 73:100 4.
114. Lopez-Fernandez MF, Lopez-Berges C, Corral M, Garcia-Talavera JR, Lopez BA, Batlle J. Assessment of multimeric structure and ristocetin-induced binding to platelets of von Willebrand factor present in cryoprecipitate and different factor VIII concentrates. Vox Sang 1987 52:15 9.
115. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Muller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998 4 (Suppl. 3 25 32.
116. Yoshioka A, Shima M, Nishino M, Yoshikawa N, Fukui H. In vitro characterization of various factor VIII concentrates. Arzneimittelforsch/Drug Res 1987 37:753 6.
117. Bernstein J, Gill JC, Leissinger C, Di PJ, Ragni MV, Shopnick R, et al. Safety and efficacy of von Willebrand factor/factor VIII concentrate (Humate-P) for prophylaxis of excessive bleeding during elective surgery in patients with von Willebrand disease. Blood 2006 108:98b (abstract 4076).
118. Di Paola J, Gill JC, Bernstein J, Leissinger C, Ragni MV, Shopnick R, et al. Pharmacokinetic evaluation of von Willebrand factor/factorVIII concentrate (Humate-P) prior to elective surgery in patients with von Willebrand disease. Blood 2006 108:98b 99b (abstract 4077).
119. Gill JC, Leissinger C, Di PJ, Bernstein J, Ragni MV, Shopnick R, et al. von Willebrand Factor /Factor VIII Concentrate (Humate-P) is safe and effective in the prevention of perioperative bleeding in patients with very low von Willebrand Factor: Ristocetin Cofactor (VWF:RCo). Blood 2006 108:97b (abstract 4071).
120. Gill JC, Leissinger C, Di PJ, Bernstein J, Ragni MV, Shopnick R, et al. Von Willebrand factor/factor VIII concentrate effectively prevents excessive bleeding in patients with very low VWF:RCo plasma levels. XXI Congress of the International Society on Thrombosis and Haemostasis, 6-12 July, Geneva, Switzerland, 2007 (abstract and poster P-S-224).
121. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007 5:1420 30.
122. Mannucci PM Dose linerarity of a von Willebrand/factor VIII concentrate (Haemate P) in elective surgery in von Willebrand disease patients. Blood 2003 102:312a (abstract 1121).
123. Berntorp E. Von Willebrand factor containing factor VIII concentrates. Haemophilia 1999 5 (Suppl. 2 60 3.
124. Schimpf K. Hämophilie und Hepatitis. Die gelben Hefte 1980 20:159 64.
125. Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J (Clin Res Ed) 1983 287:1754 7.
126. Schimpf K Die Behandlung der Hämophilie. In:Wenzel E, Hellstern P, Morgenstern E, Köhler M, von Blohn G eds. Rationelle Therapie und Diagnose von hämorrhagischen und thrombophilen Diathesen. Verhandlungsbericht der 29. Tagung der Deutschen Arbeitsgemeinschaft für Blutgerrinungsforschung in Saarbrücken, February 1985. Stuttgart, New York:F.K. Schattauer Verlag, 1986:3.4 14.
127. Schramm W, Roggendorf M, Rommel F, Kammerer R, Pohlmann H, Rasshofer R, et al. Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs. Blut 1989 59:390 2.
128. Schramm W, Gürtler L, Spannagl M, Eberle J, Wernicke D, Deinhardt F HTLV III-Antikörper bei Hämophilie-Patienten - Klinische und virologische Untersuchungen. In:Wenzel E, Hellstern P, Morgenstern E, Köhler M, von Blohn G eds. Rationelle Therapie und Diagnose von hämorrhagischen und thrombophilen Diathesen. Verhandlungsbericht der 29. Tagung der Deutschen Arbeitsgemeinschaft für Blutgerrinungsforschung in Saarbrücken, Februar 1985. Stuttgart, New York:F.K. Schattauer Verlag, 1986:3.48 50.
129. Heimburger N, Schwinn H, Gratz P, Luben G, Kumpe G, Herchenhan B. [Factor VIII concentrate, highly purified and heated in solution]. Arzneimittelforschung 1981 31:619 22 (author's transl.).
130. Delvos U, Weidmann E, Hilfenhaus J, Mauler R. Safety of pasteurised factor VIII (Haemate HS). Lancet 1988 2:1141 2.
131. Hilfenhaus J, Weidmann E. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates. Arzneimittelforsch/ Drug Res 1986 36:621 5.
132. Groener A, Schäfer W, Vey M Removal of prions by the manufacturing process of Haemate P/Humate-P. Blood 2005 106 (abstract 4171).
133. Nowak T, Schäfer W, Gröner A An integrated approach to effective pathogen reduction for a plasma-derived vWF/FVIII concentrate. XXI Congress of the International Society on Thrombosis and Haemostasis, 6-12 July, Geneva, Switzerland, 2007 (abstract P-M-099).
134. Schneppenheim R, Plendl H, Budde U. Luminography - an alternative assay for detection of von Willebrand factor multimers. Thromb Haemost 1988 60:133 6.
135. Zimmerman TS, Ruggeri ZM. Von Willebrand's disease. Clin Haematol 1983 12:175 200.
136. Weinstein M, Deykin D. Comparison of factor VIII-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate. Blood 1979 53:1095 105.
137. Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Haemate P) in von Willebrand's disease. Vox Sang 1989 56:212 7.
138. Berntorp E. Plasma product treatment in various types of von Willebrand's disease. Haemostasis 1994 24:289 97.
139. Czapek EE, Gadarowski JJ, Ontiveros JD, Pedraza JL. Humate-P for treatment of von Willebrand disease. Blood 1988 72:1100.
140. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998 4 (Suppl. 3 33 9.
141. Fukui H, Nishino M, Terada S, Nishikubo T, Yoshioka A, Kinoshita S, et al. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease. Blut 1988 56:171 8.
142. Goldsmith JC, Phillips MD, Schwartz BA Successful treatment of urgent life or limb threatening bleeding or emergent surgery in von Willebrand disease (VWD) with Humate-P (factor VIII/VWF concentrate). Blood 1999 94 (Suppl. 1 237a (abstract 1047).
143. Hach-Wunderle V. Diagnostik und Therapie des von Willebrand-Syndroms [Diagnostics and therapy of the von Willebrand syndrome]. Medwelt 1987 38:1654 7.
144. Koehler M, Hellstern P, Wenzel E. The use of heat-treated factor VIII concentrates in von Willebrand's disease. Blut 1985 50:25 7.
145. Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B. Haemate P in children with von Willebrand's disease. Haemostasis 1994 24:304 10.
146. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002 87:224 30.
147. Scharrer I. The treatment of von Willebrand's disease. In:Lusher JM, Kessler CM, eds. Hemophilia and von Willebrand's Disease in the 1990s. Amsterdam, New York, Oxford:Elsevier Science Publishers BV, 1991:463 9.
148. Scharrer I, Vigh T, Ygoren-Pursun E. Experience with Haemate P in von Willebrand's disease in adults. Haemostasis 1994 24:298 303.
149. Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost 1993 19:37 47.
150. Takahashi H, Tatewaki W, Nagayama R, Hanano M, Tamura M, Yamaguchi T, et al. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease. Haemostasis 1987 17:353 60.
151. Aledort LM. Von Willebrands's disease: a therapeutic challenge. Biomedical Progress 1991 4:43 6.
152. Budde U, Metzner HJ, Muller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006 32:626 35.
153. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992 79:3130 7.
154. Suiter TM, Budde U, Metzner HJ, Muysers C, Walter O Comparison of von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF-collagen-binding-assays in VWF/FVIII-concentrates. J Thromb Haemost. 2003 1 (Suppl. 1 abstract P1667).
155. Walter O, Budde U, Metzner HJ, Muysers C, Suiter TM Comparative evaluation of high-molecular-weight von Willebrand factor multimers and their impact on VWF-activity in different VWF/FVIII-concentrates. Ann Hematol 2003 82 (Suppl. 1 S90 (abstract 320).
156. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease Type III. Ann Hematol 1992 65:253 9.
157. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992 62:193 9.
158. Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003 9:688 95.
159. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004 10:42 51.
160. Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002 99:450 6.
161. Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 1994 71:173 9.
162. Messori A, Morfini M, Blomback M, Cinotti S, Longo G, Schimpf K, et al. Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity. Thromb Res 1992 65:699 708.
163. Schimpf K, Mannucci PM, Kreuz W, Brackmann HH, Auerswald G, Ciavarella N, et al. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 1987 316:918 22.
164. Blanchette V, Israels SJ, Akabutu J, Bergman GE Report on the efficacy of Haemate P in Canadian von Willebrand disease (vWd) patients. Thromb Haemost 1997 Suppl. 513 4 (abstract PS-2100).
165. Pai M, Robinson S, Teitel J, Bergman GE Haemate P dosing trends among 97 Canadian von Willebrand disease (vWd) patients. Thromb Haemost 1997 Suppl. 513 (abstract PS-2098).
166. Auerswald G Continuous infusion of factor VIII after elective surgery in
167. Auerswald G, Auberger K, Kreuz W, Sutor A, Deinhard M, Roth U, et al. Continuous infusion of factor VIII after elective surgery in children with haemophilia A and von Willebrand disease. Haemophilia 1996 2 (Suppl. 1 145 (abstract 553).
168. Auerswald G. Kontinuierliche Infusion von Faktoren-Konzentraten nach Operation bei Kindern mit Hämophilie. Die gelben Hefte 1997 37:191 8.
169. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, et al. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003 88:1279 83.
170. Kurth AA, Ludwig G, Scharrer I. [Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients]. Orthopaede 1999 28:366 74.
171. Scharrer I. Surgery in von Willebrand disease patients. Biomed Progr 2002 15:18 22.
172. Michiels JJ, Berneman ZN, van der PM, Schroyens W, Budde U, van Vliet HH. Bleeding prophylaxis for major surgery in patients with Type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate P). Blood Coagul Fibrinolysis 2004 15:323 30.
173. Federici AB, Morfini M, Castaman G, Zanon E, Coppola A, Franchini M, et al. Multicenter retrospective survey on efficacy and safety of Haemate P in a large cohort of Italian patients with von Willebrand disease. Haemophilia 2006 12 (Suppl. 2 abstract PO 897).
174. Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, et al. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007 92:944 51.
175. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lorenz C, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian hemophilia centers. Haemophilia 2005 11:504 9.
176. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004 10:243 9.
177. Koster T, Rosendaal FR, Reitsma PH, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994 71:719 22.
178. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995 345:152 5.
179. Kim W, Lee SY, Kim SW, Kwak JY, Kang SK, Park SK. Renal infarction in a patient with von Willebrand disease. Nephrol Dial Transplant 2000 15:1711 3.
180. Tao Z, Wang Y, Choi H, Bernardo A, Nishio K, Sadler JE, et al. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood 2005 106:141 3.
181. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002 88:387 8.
182. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002 88:378 9.
183. Schimpf K, Brackmann HH, Kreuz W, Kraus B, Haschke F, Schramm W, et al. Absence of anti-human immunodeficiency virus Types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate. N Engl J Med 1989 321:1148 52.
184. Kreuz WD, Ebener U, Krackhardt B, Werner A, Nowak-Göttl U, Wegerich B, et al. No HIV-1 and HIV-2 infection in children with hemophilia and von Willebrand disease treated with pasteurized factor VIII products since 1979/80. Blut 1989 59:345 (abstract 401).
185. Kreuz W, Auerswald G, Brückmann C, Funk M, Sutor AH, Schramm W, et al. Eleven years of virus safety (HCV, PARVO B19, HBV, HIV) with pasteurized clotting factor concentrates. Ann Hematol 1991 62:A54 (abstract 72).
186. Kreuz W, Auerswald G, Roggendorf M, Schwarz T, Funk M, Linde R, et al. Anti-HCV and anti-B 19 Prävalenz nach Substitution mit pasteurisierten Gerinnungspräparaten bei bisher unbehandelten Patienten. 21. Hämophilie-Symposion Hamburg 1990:Springer-Verlag, 1991 164 9.
187. Kreuz W, Auerswald G, Brückmann C, Linde R, Sutor AH, Schramm W, et al. Virus safety of pasteurized clotting factor concentrates - an eleven year follow up. Thromb Haemost 1991 65:824 (abstract 491).
188. Kreuz W, Klarmann D, Auerswald G, Ehrenforth S, Linde R, Mentzer D, et al. Prävalenz von Anti-Hepatitis A und Anti-Parvo B 19 bei Kindern mit Blutgerinnungsstörungen. 23 Hämophilie-Symposion Hamburg 1992:Springer-Verlag, 1993 48.
189. Kreuz W, Klarmann D, Auerswald G, Ehrenforth S, Linde R, Mentzer D, et al. Anti-HCV Prävalenz bei Kindern mit Blutgerinnungsstörungen - Untersuchungsergebnisse mit dem Test der 1. und 2. Generation. 23. Hämophilie-Symposion Hamburg 1992:Springer-Verlag, 1993 56.
190. Kreuz W, Klarmann D, Auerswald G, Auberger K, Gurtler L, Rabenau H, et al. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease. Lancet 1993 341:446.
191. Kreuz W, Auerswald G, Auberger K, Klarmann D, Zieger B, Huth-Kühne A, et al. Anti-HCV Prevalence in children with haemophilia and other coagulation disorders - results of the first and second generation test. Ann Hematol 1993 66 (Suppl. 1 A49 (abstract 186).
192. Kreuz W, Auerswald G, Auberger K, Klarmann D, Zieger B, Huth-Kühne A, et al. Prevalence of anti-hepatitis A and Anti-Parvo B19 in children with haemophilia and other coagulation disorders. Ann Hematol 1993 66 (Suppl. 1 A49 (abstract 185).
193. Kreuz W, Klarmann D, Auerswald G, Ehrenforth S, Linde P, Mentzer D, et al. Prävalenz von Anti-Hepatitis A und Anti-Parvo B 19 bei Kindern mit Blutgerinnungsstörungen. 23. Hämophilie-Symposion Hamburg 1992:Springer-Verlag, 1993 210 3 W, Klarmann D, Auerswald G, Auberger K, Zieger B, Sutor AH, et al. Absence of Hepatitis A after treatment with pasteurised factor VIII concentrates in children with coagulation disorders. XXI International Congress of the World Federation of Hemophilia, 24-29 April, Mexico City, Mexico, 1994 (abstract 256).
194. Federici AB, Santagostino E, Rumi MG, Russo A, Mancuso ME, Soffredini R, et al. The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study. Haematologica 2006 91:503 8.
195. Vey M, Wiegand T, Baron H, Gröner A Prion removal in the production of coagulation factor concentrate Humate-P from Human Plasma. Blood 2001 98:112b (abstract 4096).
196. Schäfer W, Gnau O, Seyfert-Brandt W, Wiegand T, Vey M, Groschup M, et al. Removal of prions by the manufacturing process of the VWF/FVIII coagulation concentrate Haemate P/Humate-P. XXVII International Congress of the World Federation of Hemophilia, 21-25 May, Vancouver, Canada, 2006 (poster 042).
197. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996 2:95 9.
198. Kreuz W, Scharrer I Elimination of Factor VIII inhibitors in 6 children with severe hemophilia A. XVI International Congress of the World Federation of Hemophilia, 24-28 August, Rio de Janeiro, Brazil, 1984 (abstract 178).
199. Kreuz W, Scharrer I Elimination der Faktor VIII-Hemmkörper bei 7 Kindern mit schwerer Hämophilie A. 29. Jahrestagung der Deutschen Arbeitsgemeinschaft für Blutgerrinungsforschung in Saarbrücken, February 1985 Saarbrucken, Germany:79 83 (presentation 1.3.3).
200. Kreuz WD, Krackhardt B, Scharrer I Elimination of factor VIII inhibitors in children by induction of immune tolerance - 10 years of experience. Blut 1989 59:290 (abstract 183).
201. Kreuz W, Ehrenforth S, Auerswald G, Linde R, Beeg T, Mentzer D, et al. Factor VIII inhibitors in haemophilia A; the importance of early and continuous administration of high-dose factor VIII and APCC for the successful treatment and induction of immunotolerance. XX International Congress of the World Federation of Hemophilia, 12-17 October, Athens, Greece, 1992 (abstract 356).
202. Kreuz W, Joseph-Steiner J, Mentzer D, Auerswald G, Beeg T, Becker S Successful immune tolerance therapy of FVIII-inhibitor in children after changing from high to intermediate purity FVIII concentrate. Ann Hematol 1996 72 (Suppl. I A85 (abstract 339).
203. Kreuz W, Mentzer D, Auerswald G, Becker S, Joseph-Steiner J Successful immunetolerance therapy of FVIII-Inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia 1996 2 (Suppl. I abstract 73).
204. Kreuz W, Ettingshausen CE, Auerswald G, Heidemann P, Kemkes-Matthes B, Gnekow A, et al. Immune tolerance therapy in patients with hemophilia A and inhibitors using pd FVIII concentrates with high content of VWF. Ann Hematol 2000 79 (Suppl. I A77 (abstract P140).
205. Mentzer D, Kreuz W, Auerswald G Erfolgreiche Faktor VIII- Hemmkörperelimination nach Wechsel von 'high'- zu 'intermediate'-purity Faktor-VIII-Konzentrat bei Kindern mit Hämophilie A. 27. Hämophilie-Symposion Hamburg 1996:Springer-Verlag, 1998 187 94.
206. Scaraggi FA High dose of an intermediate purity factor VIII concentrate for induction of immune tolerance in severe haemophilia A with factor VIII inhibitor. Haemophilia 2006 12 (Suppl. 2 abstract PO 422).
207. Ritchie B, Woodman RC, Poon MC. Deep venous thrombosis in hemophilia A. Am J Med 1992 93:699 700.
208. Stewart AJ, Manson LM, Dennis R, Allan PL, Ludlam CA. Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A. Haemophilia 2000 6:47 9.
209. Pollmann H, Richter H Prevalence of hepatitis and HIV in a Group of haemophiliacs. Ann Hematol 1994 68 (Suppl. II abstract 331).
210. Pollmann H, Richter H, Kahl B, Peters G 15 years experience with virus safety of pasteurised factor VIII concentrates in Germany. Haemophilia 1996 2 (Suppl. 1 24 (abstract 91).
211. Köhler-Vajta K, Belohradsky B, Gürtler L Treatment of hemophiliac children with Haemate HS Behringwerke, a 10 years study on viral safety. Thromb Haemost 1989 62:210 (abstract 643).
212. Köhler-Vajta K, Gürtler L, Froesner G 15 years experience on viral safety of a pasteurized factor VIII concentrate in pediatric patients and young adults. Thromb Haemost 1995 73:1017 (abstract 452).
213. Klarmann D, Kreuz W, Auerswald G, Auberger K, Rabenau H, Gurtler L, et al. Hepatitis C and pasteurised factor VIII and IX concentrates. Thromb Haemost 1995 73:736 7.
214. Kreuz W, Becker S, Auerswald G, Kurnick K, Kroniger A, Klarmann D. Virus safety of pasteurized clotting factor concentrates. Semin Thromb Hemost 2002 28 (Suppl. 1 57 62.
215. Schulman S, Lindgren AC, Petrini P, Allander T. Transmission of hepatitis C with pasteurised factor VIII. Lancet 1992 340:305 6.
216. Favaloro EJ, Lillicrap D, Lazzari MA, Cattaneo M, Mazurier C, Woods A, et al. von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004 10 (Suppl. 4 164 8.
217. Manno CS, Butler RB, Cohen AR. Low recovery in vivo of highly purified factor VIII in patients with hemophilia. J Pediatr 1992 121:814 8.
218. Nadler SB, Hidalgo J, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962 51:224 32.